SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-021670
Filing Date
2023-06-16
Accepted
2023-06-16 16:15:22
Documents
12
Period of Report
2023-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48556
  Complete submission text file 0001493152-23-021670.txt   219072

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vodg-20230613.xsd EX-101.SCH 2977
3 XBRL LABEL FILE vodg-20230613_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE vodg-20230613_pre.xml EX-101.PRE 22371
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3294
Mailing Address 4621 TECHNOLOGY DRIVE GOLDEN CO 80403
Business Address 4621 TECHNOLOGY DRIVE GOLDEN CO 80403 (720) 859-4120
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

IRS No.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 000-17378 | Film No.: 231021287
SIC: 2836 Biological Products, (No Diagnostic Substances)